InMed Pharmaceuticals Inc. Stock Toronto S.E.
Equities
IN
CA4576376012
Biotechnology & Medical Research
Sales 2024 * | 7.3M 5.3M | Sales 2025 * | 9.12M 6.63M | Capitalization | 2.41M 1.75M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.33 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.26 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 13 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.64% |
Latest transcript on InMed Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-15 |
Chief Operating Officer | - | 18-11-04 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 22-02-10 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-15 |
Andrew Hull
CHM | Chairman | 61 | 16-09-11 |
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.11% | 96.37B | |
-1.80% | 21.37B | |
-17.75% | 20.92B | |
-6.91% | 18.64B | |
-42.00% | 16.4B | |
-28.19% | 13.53B | |
+19.90% | 10.85B | |
-23.23% | 8.4B |